India Panel No-Go For Lilly’s Antibody In COVID-19

More Data Required?

India expert panel decides not to back Lilly’s bamlanivimab as a COVID-19 therapy, at least for now, under the accelerated approval route and without local trials, but the US firm is still pursuing an authorization request. Physicians underscore the need for more data on important patient outcomes for the antibody product.

YES and NO acceptance and rejection symbols vector for vote, election choice. Brush painted symbolic approval icons in square frames. Tick and cross signs, check marks graphic design. - Vector
Lilly Pursues Regulatory Approval For Bamlanivimab In India • Source: Shutterstock

Eli Lilly and Company’s investigational neutralizing antibody bamlanivimab has not been endorsed, at least not immediately, by an Indian expert panel as a treatment for COVID-19 via the expedited trial waiver route.

The no-go by the Indian Subject Expert Committee (SEC) came even as the drug received an Emergency Use Authorization (EUA)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from India

More from Asia